Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Comment by KVDollarson Jul 20, 2021 3:31pm
98 Views
Post# 33576398

RE:RE:Earnings Forecast - Revenue Potential is 61 million in 2021

RE:RE:Earnings Forecast - Revenue Potential is 61 million in 2021Good post.

Fingers crossed..  let's see wheere it goes now.

once the 75 mil is revelead and they have avalanches of news regarding - trials, fda, selling and even bigger partnerships (akap Pfizer if true)

This should fly

Cant wait for it to unfold -- Since covid goin back up, covid stocks should start rising agian.


Hiddensecrets wrote: From the press release of the $ 12 million, it states as 1st priority, INVESTMENT IN BUSINESS OPPORTUNITIES.

And what opportunity can be bigger than blowfish at this moment as world is giving up on COVID19 with businesses being unable to open?

With regards to the other 75 million shares, they will become public.   There is a timeline, not sure of it, but could be within 15 days from closure of PP. 

I think that the 75 million share investment + usage of $ 12 million is all tied in.

For example:  it could be Pfizer with $ 75 million share investment, to conclude distribution contract with MEDV and, MEDV uses part of the $ 12 million to acquire its 40% interest or more. 

We will know soon enough.

One thing for sure,  STAN BHARTI does not invest millions cause he has nothing to do.  He is sitting on some MEGA NEWS.

mpo


<< Previous
Bullboard Posts
Next >>